Cargando…
Alzheimer’s Disease: Biomarkers in the Genome, Blood, and Cerebrospinal Fluid
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder that slowly destroys memory and thinking skills, resulting in behavioral changes. It is estimated that nearly 36 million are affected globally with numbers reaching 115 million by 2050. AD can only be definitively diagnosed at auto...
Autores principales: | Huynh, Rose Ann, Mohan, Chandra |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5357660/ https://www.ncbi.nlm.nih.gov/pubmed/28373857 http://dx.doi.org/10.3389/fneur.2017.00102 |
Ejemplares similares
-
Comparison of Cerebrospinal Fluid Amyloidogenic Nanoplaques With Core Biomarkers of Alzheimer’s Disease
por: Aksnes, Mari, et al.
Publicado: (2021) -
Cerebrospinal fluid microRNAs as potential biomarkers in Alzheimer’s disease
por: Noor Eddin, Ahmed, et al.
Publicado: (2023) -
Cerebrospinal fluid biomarkers for differentiation of frontotemporal lobar degeneration from Alzheimer's disease
por: Irwin, David J., et al.
Publicado: (2013) -
Pro-Apoptotic Kinase Levels in Cerebrospinal Fluid as Potential Future Biomarkers in Alzheimer’s Disease
por: Paquet, Claire, et al.
Publicado: (2015) -
A Strategy for Discovery and Verification of Candidate Biomarkers in Cerebrospinal Fluid of Preclinical Alzheimer’s Disease
por: Zhong, Xiaofang, et al.
Publicado: (2019)